# Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer

> **NCT02695550** · PHASE1 · UNKNOWN · sponsor: **Centaurus Biopharma Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** CT-707

## Key facts

- **NCT ID:** NCT02695550
- **Lead sponsor:** Centaurus Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02695550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02695550, "Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02695550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*